Obesity and renal cancer: Role of adipokines in the tumor-immune system conflict

OncoImmunology

Volumn 3, Issue 1, 2014, Pages

  Gati, Asma ^a   Kouidhi, Soumaya ^a   Marrakchi, Raja ^a   Gaaied, Amel El ^a   Kourda, Nadia ^b   Derouiche, Amine ^b   Chebil, Mohamed ^b   Caignard, Anne ^c   Perier, Aurélie ^c,d  

^a FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

^b CHARLES NICOLLE HOSPITAL   (Tunisia)

^c INSTITUT COCHIN   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Adipokines; Immune response; Obesity; Renal cell carcinoma

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; LEPTIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ANGIOGENESIS; BODY MASS; CANCER MORTALITY; CANCER PROGNOSIS; CARCINOGENESIS; CHRONIC INFLAMMATION; CYTOKINE RELEASE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HYPOXIA; IMMUNOCOMPETENCE; IMMUNOMODULATION; KIDNEY CANCER; KIDNEY CARCINOMA; MESENCHYMAL STEM CELL; NONHUMAN; OBESITY; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84899045418     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27810     Document Type: Review

References (80)

1. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008; 34:193-205; PMID:18313224; http://dx.doi.org/10.1016/j. ctrv.2007.12.001.
2. Dhote R, Thiounn N, Debré B, Vidal-Trecan G. Risk factors for adult renal cell carcinoma. Urol Clin North Am 2004; 31:237-47; PMID:15123404; http://dx.doi.org/10.1016/j.ucl.2004.01.004.
3. Duan XF, Tang P, Li Q, Yu ZT. Obesity, adipokines and hepatocellular carcinoma. Int J Cancer 2013; 133:1776-83; PMID:23404222; http://dx.doi. org/10.1002/ijc.28105.
4. McGuire BB, Fitzpatrick JM. BMI and the risk of renal cell carcinoma. Curr Opin Urol 2011; 21:356-61; PMID:21730854; http://dx.doi.org/10.1097/MOU.0b013e32834962d5.
5. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371:569-78; PMID:18280327; http://dx.doi.org/10.1016/S0140-6736(08)60269-X.
6. Dal Maso L, Zucchetto A, Tavani A, Montella M, Ramazzotti V, Talamini R, Canzonieri V, Garbeglio A, Negri E, Tonini A, et al. Renal cell cancer and body size at different ages: an Italian multicenter case-control study. Am J Epidemiol 2007; 166:582-91; PMID:17591592; http://dx.doi.org/10.1093/aje/kwm108.
7. Lowrance WT, Thompson RH, Yee DS, Kaag M, Donat SM, Russo P. Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies. BJU Int 2010; 105:16-20; PMID:19583732; http://dx.doi. org/10.1111/j.1464-410X.2009.08706.x.
8. da Costa WH, Moniz RR, da Cunha IW, Fonseca FP, Guimaraes GC, de Cássio Zequi S. Impact of renal vein invasion and fat invasion in pT3a renal cell carcinoma. BJU Int 2012; 109:544-8; PMID:21711437; http://dx.doi.org/10.1111/j.1464-410X.2011.10366.x.
9. Choi Y, Park B, Jeong BC, Seo SI, Jeon SS, Choi HY, Adami HO, Lee JE, Lee HM. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. Int J Cancer 2013; 132:625-34; PMID:22610826; http://dx.doi. org/10.1002/ijc.27639.
10. Rogde AJ, Gudbrandsdottir G, Hjelle KM, Sand KE, Bostad L, Beisland C. Obesity is associated with an improved cancer-specific survival, but an increased rate of postoperative complications after surgery for renal cell carcinoma. Scand J Urol Nephrol 2012; 46:348-57; PMID:22530756; http://dx.doi.org/10. 3109/00365599.2012.678382.
11. Imagawa K, Numata Y, Katsuura G, Sakaguchi I, Morita A, Kikuoka S, Matumoto Y, Tsuji T, Tamaki M, Sasakura K, et al. Structure-function studies of human leptin. J Biol Chem 1998; 273:35245-9; PMID:9857064; http://dx.doi.org/10.1074/jbc.273.52.35245.
12. Basak S, Duttaroy AK. Leptin induces tube formation in first-trimester extravillous trophoblast cells. Eur J Obstet Gynecol Reprod Biol 2012; 164:24-9; PMID:22717511; http://dx.doi.org/10.1016/j. ejogrb.2012.05.033.
13. Newman G, Gonzalez-Perez RR. Leptin-cytokine crosstalk in breast cancer. Mol Cell Endocrinol 2013; PMID:23562747.
14. Newman G, Gonzalez-Perez RR. Leptin-cytokine crosstalk in breast cancer. Mol Cell Endocrinol 2014; 382:570-82; PMID:23562747; http://dx.doi. org/10.1016/j.mce.2013.03.025.
15. Cleary MP, Phillips FC, Getzin SC, Jacobson TL, Jacobson MK, Christensen TA, Juneja SC, Grande JP, Maihle NJ. Genetically obese MMTVTGF-alpha/Lep(ob)Lep(ob) female mice do not develop mammary tumors. Breast Cancer Res Treat 2003; 77:205-15; PMID:12602920; http://dx.doi. org/10.1023/A:1021891825399.
16. Cleary MP, Juneja SC, Phillips FC, Hu X, Grande JP, Maihle NJ. Leptin receptor-deficient MMTV-TGFalpha/Lepr(db)Lepr(db) female mice do not develop oncogene-induced mammary tumors. Exp Biol Med (Maywood) 2004; 229:182-93; PMID:14734797.
17. Perera CN, Chin HG, Duru N, Camarillo IG. Leptin-regulated gene expression in MCF-7 breast cancer cells: mechanistic insights into leptinregulated mammary tumor growth and progression. J Endocrinol 2008; 199:221-33; PMID:18715880; http://dx.doi.org/10.1677/JOE-08-0215.
18. Eto I. Expression of p27Kip1, a cell cycle repressor protein, is inversely associated with potential carcinogenic risk in the genetic rodent models of obesity and long-lived Ames dwarf mice. Metabolism 2013; 62:873-87; PMID:23357529; http://dx.doi. org/10.1016/j.metabol.2013.01.001.
19. Caldefie-Chézet F, Dubois V, Delort L, Rossary A, Vasson MP. [Leptin: Involvement in the pathophysiology of breast cancer]. Ann Endocrinol (Paris) 2013; 74:90-101; PMID:23566612.
20. Ptak A, Kolaczkowska E, Gregoraszczuk EL. Leptin stimulation of cell cycle and inhibition of apoptosis gene and protein expression in OVCAR-3 ovarian cancer cells. Endocrine 2013; 43:394-403; PMID:22968658; http://dx.doi.org/10.1007/s12020-012-9788-7.
21. Liao LM, Schwartz K, Pollak M, Graubard BI, Li Z, Ruterbusch J, Rothman N, Davis F, Wacholder S, Colt J, et al. Serum leptin and adiponectin levels and risk of renal cell carcinoma. Obesity (Silver Spring) 2013; 21:1478-85; PMID:23666639; http://dx.doi. org/10.1002/oby.20138.
22. Horiguchi A, Sumitomo M, Asakuma J, Asano T, Zheng R, Asano T, Nanus DM, Hayakawa M. Leptin promotes invasiveness of murine renal cancer cells via extracellular signal-regulated kinases and rho dependent pathway. J Urol 2006; 176:1636-41; PMID:16952706; http://dx.doi.org/10.1016/j. juro.2006.06.040.
23. Horiguchi A, Sumitomo M, Asakuma J, Asano T, Zheng R, Asano T, Nanus DM, Hayakawa M. Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma. J Urol 2006; 176:1631-5; PMID:16952705; http://dx.doi. org/10.1016/j.juro.2006.06.039.
24. Li L, Gao Y, Zhang LL, He DL. Concomitant activation of the JAK/STAT3 and ERK1/2 signaling is involved in leptin-mediated proliferation of renal cell carcinoma Caki-2 cells. Cancer Biol Ther 2008; 7:1787-92; PMID:18787400; http://dx.doi. org/10.4161/cbt.7.11.6837.
25. Mao X, Hong JY, Dong LQ. The adiponectin signaling pathway as a novel pharmacological target. Mini Rev Med Chem 2006; 6:1331-40; PMID:17168809; http://dx.doi.org/10.2174/138955706778992978.
26. Scheid MP, Sweeney G. The role of adiponectin signaling in metabolic syndrome and cancer. Rev Endocr Metab Disord 2013; Forthcoming; PMID:24019064; http://dx.doi.org/10.1007/s11154-013-9265-5.
27. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer 2006; 94:1221-5; PMID:16570048; http://dx.doi. org/10.1038/sj.bjc.6603051.
28. Kim KY, Kim JK, Han SH, Lim JS, Kim KI, Cho DH, Lee MS, Lee JH, Yoon DY, Yoon SR, et al. Adiponectin is a negative regulator of NK cell cytotoxicity. J Immunol 2006; 176:5958-64; PMID:16670304.
29. Wang Y, Lam KS, Xu JY, Lu G, Xu LY, Cooper GJ, Xu A. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 2005; 280:18341-7; PMID:15734737; http://dx.doi. org/10.1074/jbc.M501149200.
30. Man K, Ng KT, Xu A, Cheng Q, Lo CM, Xiao JW, Sun BS, Lim ZX, Cheung JS, Wu EX, et al. Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling. Clin Cancer Res 2010; 16:967-77; PMID:20103676; http://dx.doi.org/10.1158/1078-0432.CCR-09-1487.
31. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000; 96:1723-32; PMID:10961870.
32. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8:731-7; PMID:12068289; http://dx.doi. org/10.1038/nm724.
33. Horiguchi A, Asano T, Asano T, Ito K, Sumitomo M, Hayakawa M. Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma. J Urol 2008; 180:1137-40; PMID:18639282; http://dx.doi. org/10.1016/j.juro.2008.04.135.
34. Pinthus JH, Kleinmann N, Tisdale B, Chatterjee S, Lu JP, Gillis A, Hamlet T, Singh G, Farrokhyar F, Kapoor A. Lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear-cell carcinoma of the kidney. Eur Urol 2008; 54:866-73; PMID:18343565; http://dx.doi. org/10.1016/j.eururo.2008.02.044.
35. Kleinmann N, Duivenvoorden WC, Hopmans SN, Beatty LK, Qiao S, Gallino D, Lhotak S, Daya D, Paschos A, Austin RC, et al. Underactivation of the adiponectin-adiponectin receptor 1 axis in clear cell renal cell carcinoma: implications for progression. Clin Exp Metastasis 2013; Forthcoming; PMID:24096711; http://dx.doi.org/10.1007/s10585-013-9618-1.
36. Grivennikov SI, Karin M. Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev 2010; 20:65-71; PMID:20036794; http://dx.doi.org/10.1016/j.gde.2009.11.004.
37. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7; PMID:12490959; http://dx.doi.org/10.1038/nature01322.
38. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j. cell.2011.02.013.
39. Meijer K, de Vries M, Al-Lahham S, Bruinenberg M, Weening D, Dijkstra M, Kloosterhuis N, van der Leij RJ, van der Want H, Kroesen BJ, et al. Human primary adipocytes exhibit immune cell function: adipocytes prime inflammation independent of macrophages. PLoS One 2011; 6:e17154; PMID:21448265; http://dx.doi.org/10.1371/journal.pone.0017154.
40. Harvey AE, Lashinger LM, Hursting SD. The growing challenge of obesity and cancer: an inflammatory issue. Ann N Y Acad Sci 2011; 1229:45-52; PMID:21793838; http://dx.doi. org/10.1111/j.1749-6632.2011.06096.x.
41. Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol 2010; 184:873-8; PMID:20643463; http://dx.doi. org/10.1016/j.juro.2010.05.028.
42. Fitzgerald JP, Nayak B, Shanmugasundaram K, Friedrichs W, Sudarshan S, Eid AA, DeNapoli T, Parekh DJ, Gorin Y, Block K. Nox4 mediates renal cell carcinoma cell invasion through hypoxiainduced interleukin 6-and 8-production. PLoS One 2012; 7:e30712; PMID:22303451; http://dx.doi. org/10.1371/journal.pone.0030712.
43. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32; PMID:13130303; http://dx.doi.org/10.1038/nrc1187.
44. Catalán V, Gómez-Ambrosi J, Rodríguez A, Frühbeck G. Adipose tissue immunity and cancer. Front Physiol 2013; 4:275; PMID:24106481; http://dx.doi.org/10.3389/fphys.2013.00275.
45. Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, Coupaye M, Pelloux V, Hugol D, Bouillot JL, et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005; 54:2277-86; PMID:16046292; http://dx.doi. org/10.2337/diabetes.54.8.2277.
46. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 2005; 209-31; PMID:15617481.
47. Gómez-Ambrosi J, Catalán V, Rodríguez A, Ramírez B, Silva C, Gil MJ, Salvador J, Frühbeck G. Involvement of serum vascular endothelial growth factor family members in the development of obesity in mice and humans. J Nutr Biochem 2010; 21:774-80; PMID:19615882; http://dx.doi.org/10.1016/j. jnutbio.2009.05.004.
48. George DJ, Kaelin WG Jr. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 2003; 349:419-21; PMID:12890838; http://dx.doi.org/10.1056/NEJMp030061.
49. Ladoire S, Bonnetain F, Gauthier M, Zanetta S, Petit JM, Guiu S, Kermarrec I, Mourey E, Michel F, Krause D, et al. Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents. Oncologist 2011; 16:71-81; PMID:21212435; http://dx.doi.org/10.1634/theoncologist.2010-0227.
50. Kidd S, Spaeth E, Watson K, Burks J, Lu H, Klopp A, Andreeff M, Marini FC. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS One 2012; 7:e30563; PMID:22363446; http://dx.doi.org/10.1371/journal.pone.0030563.
51. Zhang Y, Daquinag A, Traktuev DO, Amaya-Manzanares F, Simmons PJ, March KL, Pasqualini R, Arap W, Kolonin MG. White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models. Cancer Res 2009; 69:5259-66; PMID:19491274; http://dx.doi. org/10.1158/0008-5472.CAN-08-3444.
52. Zhang Y, Bellows CF, Kolonin MG. Adipose tissuederived progenitor cells and cancer. World J Stem Cells 2010; 2:103-13; PMID:21607127; http://dx.doi.org/10.4252/wjsc.v2.i5.103.
53. Rodeheffer MS, Birsoy K, Friedman JM. Identification of white adipocyte progenitor cells in vivo. Cell 2008; 135:240-9; PMID:18835024; http://dx.doi.org/10.1016/j.cell.2008.09.036.
54. Kushiro K, Chu RA, Verma A, Núñez NP. Adipocytes Promote B16BL6 Melanoma Cell Invasion and the Epithelial-to-Mesenchymal Transition. Cancer Microenviron 2012; 5:73-82; PMID:21892698; http://dx.doi.org/10.1007/s12307-011-0087-2.
55. Ho MY, Tang SJ, Chuang MJ, Cha TL, Li JY, Sun GH, Sun KH. TNF-α induces epithelialmesenchymal transition of renal cell carcinoma cells via a GSK3β-dependent mechanism. Mol Cancer Res 2012; 10:1109-19; PMID:22707636; http://dx.doi. org/10.1158/1541-7786.MCR-12-0160.
56. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011; 17:1498-503; PMID:22037646; http://dx.doi.org/10.1038/nm.2492.
57. Dovio A, Caramello V, Masera RG, Sartori ML, Saba L, Tinivella M, Prolo P, Termine A, Avagnina P, Angeli A. Natural killer cell activity and sensitivity to positive and negative modulation in uncomplicated obese subjects: relationships to leptin and diet composition. Int J Obes Relat Metab Disord 2004; 28:894-901; PMID:15208649; http://dx.doi. org/10.1038/sj.ijo.0802639.
58. Nave H, Mueller G, Siegmund B, Jacobs R, Stroh T, Schueler U, Hopfe M, Behrendt P, Buchenauer T, Pabst R, et al. Resistance of Janus kinase-2 dependent leptin signaling in natural killer (NK) cells: a novel mechanism of NK cell dysfunction in dietinduced obesity. Endocrinology 2008; 149:3370-8; PMID:18356278; http://dx.doi.org/10.1210/en.2007-1516.
59. Lautenbach A, Budde A, Wrann CD, Teichmann B, Vieten G, Karl T, Nave H. Obesity and the associated mediators leptin, estrogen and IGF-I enhance the cell proliferation and early tumorigenesis of breast cancer cells. Nutr Cancer 2009; 61:484-91; PMID:19838920; http://dx.doi. org/10.1080/01635580802610115.
60. Wrann CD, Laue T, Hübner L, Kuhlmann S, Jacobs R, Goudeva L, Nave H. Short-term and long-term leptin exposure differentially affect human natural killer cell immune functions. Am J Physiol Endocrinol Metab 2012; 302:E108-16; PMID:21952038; http://dx.doi.org/10.1152/ajpendo.00057.2011.
61. Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 2000; 68:437-46; PMID:11037963.
62. Lord GM, Matarese G, Howard JK, Bloom SR, Lechler RI. Leptin inhibits the anti-CD3-driven proliferation of peripheral blood T cells but enhances the production of proinflammatory cytokines. J Leukoc Biol 2002; 72:330-8; PMID:12149424.
63. Mattioli B, Straface E, Quaranta MG, Giordani L, Viora M. Leptin promotes differentiation and survival of human dendritic cells and licenses them for Th1 priming. J Immunol 2005; 174:6820-8; PMID:15905523.
64. Fernández-Riejos P, Goberna R, Sánchez-Margalet V. Leptin promotes cell survival and activates Jurkat T lymphocytes by stimulation of mitogenactivated protein kinase. Clin Exp Immunol 2008; 151:505-18; PMID:18234059; http://dx.doi. org/10.1111/j.1365-2249.2007.03563.x.
65. Fujita Y, Murakami M, Ogawa Y, Masuzaki H, Tanaka M, Ozaki S, Nakao K, Mimori T. Leptin inhibits stress-induced apoptosis of T lymphocytes. Clin Exp Immunol 2002; 128:21-6; PMID:11982586; http://dx.doi.org/10.1046/j.1365-2249.2002.01797.x.
66. De Rosa V, Procaccini C, Calì G, Pirozzi G, Fontana S, Zappacosta S, La Cava A, Matarese G. A key role of leptin in the control of regulatory T cell proliferation. Immunity 2007; 26:241-55; PMID:17307705; http://dx.doi.org/10.1016/j.immuni.2007.01.011.
67. Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean MC, Riquet M, Crozet L, Ouakrim H, Goc J, Cazes A, et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res 2013; 19:4079-91; PMID:23785047; http://dx.doi.org/10.1158/1078-0432.CCR-12-3847.
68. Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, Levionnois E, Nizard M, Si-Mohamed A, Besnier N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013; 73:128-38; PMID:23135914; http://dx.doi.org/10.1158/0008-5472.CAN-12-2606.
69. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004; 323:630-5; PMID:15369797; http://dx.doi.org/10.1016/j. bbrc.2004.08.145.
70. Tsang JY, Li D, Ho D, Peng J, Xu A, Lamb J, Chen Y, Tam PK. Novel immunomodulatory effects of adiponectin on dendritic cell functions. Int Immunopharmacol 2011; 11:604-9; PMID:21094289; http://dx.doi.org/10.1016/j. intimp.2010.11.009.
71. Jung MY, Kim HS, Hong HJ, Youn BS, Kim TS. Adiponectin induces dendritic cell activation via PLCγ/JNK/NF-xB pathways, leading to Th1 and Th17 polarization. J Immunol 2012; 188:2592-601; PMID:22345647; http://dx.doi.org/10.4049/jimmunol.1102588.
72. Oudard S, Rixe O, Beuselinck B, Linassier C, Banu E, Machiels JP, Baudard M, Ringeisen F, Velu T, Lefrere-Belda MA, et al. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clearcell carcinoma: clinical and immunological findings. Cancer Immunol Immunother 2011; 60:261-71; PMID:21069322; http://dx.doi.org/10.1007/s00262-010-0935-9.
73. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18:1254-61; PMID:22842478; http://dx.doi.org/10.1038/nm.2883.
74. Gati A, Guerra N, Gaudin C, Da Rocha S, Escudier B, Lécluse Y, Bettaieb A, Chouaib S, Caignard A. CD158 receptor controls cytotoxic T-lymphocyte susceptibility to tumor-mediated activation-induced cell death by interfering with Fas signaling. Cancer Res 2003; 63:7475-82; PMID:14612548.
75. Guerra N, Guillard M, Angevin E, Echchakir H, Escudier B, Moretta A, Chouaib S, Caignard A. Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas. Blood 2000; 95:2883-9; PMID:10779435.
76. Eckl J, Buchner A, Prinz PU, Riesenberg R, Siegert SI, Kammerer R, Nelson PJ, Noessner E. Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging. J Mol Med (Berl) 2012; 90:55-66; PMID:21870102; http://dx.doi.org/10.1007/s00109-011-0806-7.
77. Gati A, Da Rocha S, Guerra N, Escudier B, Moretta A, Chouaib S, Angevin E, Caignard A. Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patients. Int J Cancer 2004; 109:393-401; PMID:14961578; http://dx.doi. org/10.1002/ijc.11730.
78. Schleypen JS, Von Geldern M, Weiss EH, Kotzias N, Rohrmann K, Schendel DJ, Falk CS, Pohla H. Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes. Int J Cancer 2003; 106:905-12; PMID:12918068; http://dx.doi.org/10.1002/ijc.11321.
79. Perier A, Fregni G, Wittnebel S, Gad S, Allard M, Gervois N, Escudier B, Azzarone B, Caignard A. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clearcell renal cell carcinoma. Oncogene 2011; 30:2622-32; PMID:21258414; http://dx.doi.org/10.1038/onc.2010.638.
80. Wittnebel S, Da Rocha S, Giron-Michel J, Jalil A, Opolon P, Escudier B, Validire P, Khawam K, Chouaib S, Azzarone B, et al. Membrane-bound interleukin (IL)-15 on renal tumor cells rescues natural killer cells from IL-2 starvation-induced apoptosis. Cancer Res 2007; 67:5594-9; PMID:17575122; http://dx.doi. org/10.1158/0008-5472.CAN-06-4406.